Brind.
  1. Sana Biotechnology reported financial results and received FDA feedback on its IND filing.
  2. Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital.

Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.

2 reports, 0 independent Updated Jun 29
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Per-Ola Carlsson is appointed as the study principal investigator for Sana Biotechnology's ongoing treatments.

Who's involved

What this event is mainly about
Sana BiotechnologyPer-Ola Carlsson

Keep exploring

Part of

Sana Biotechnology is advancing its IND application with GMP Master Cell Bank development and trials conducted at Uppsala University Hospital. All 2 developments

Within Sana Biotechnology reported financial results and received FDA feedback on its IND filing.

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet